MRx 109

Drug Profile

MRx 109

Alternative Names: MRx-109

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator MyeloRx
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis; Transplant rejection

Highest Development Phases

  • Preclinical Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 11 Jul 2016 Preclinical trials in Transplant rejection in USA (unspecified route)
  • 11 Jul 2016 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
  • 11 Jul 2016 MRx 109 is available for licensing as of 11 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top